성인 안구형 중증근무력증 환자를 대상으로 Rozanolixizumab의 장기적 안전성과 효능을 평가하는 연구 (MyVisionXT)
성인 안구형 중증근무력증 환자를 대상으로 로자놀리시주맙의 장기적 안전성 및 효능을 평가하기 위한 3상, 개방형, 연장 연구
The purpose of the study is to assess the long-term safety and efficacy of rozanolixizumab in adult study participants with ocular myasthenia gravis.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: UCB Cares
- 전화번호: +18445992273
- 이메일: ucbcares@ucb.com
연구 연락처 백업
- 이름: UCB Cares
- 전화번호: 00184459922733 (UCB)
- 이메일: ucbcares@ucb.com
연구 장소
-
-
-
Sarajishvili, 그루지야
- 모병
- Mg0039 21403
-
Tbilisi, 그루지야
- 모병
- Mg0039 21402
-
-
-
-
Arizona
-
Scottsdale, Arizona, 미국, 85251
- 모병
- Mg0039 10104
-
-
Ohio
-
Columbus, Ohio, 미국, 43210
- 모병
- Mg0039 10103
-
-
-
-
-
Barcelona, 스페인
- 모병
- Mg0039 20604
-
Madrid, 스페인
- 모병
- Mg0039 20611
-
Murcia, 스페인
- 모병
- Mg0039 20602
-
Málaga, 스페인
- 모병
- Mg0039 20606
-
-
-
-
-
Kobe, 일본
- 모병
- Mg0039 31802
-
Minatoku, 일본
- 모병
- Mg0039 31804
-
Sendai, 일본
- 모병
- Mg0039 31805
-
-
-
-
-
Beijing, 중국
- 모병
- Mg0039 31901
-
Beijing, 중국
- 모병
- Mg0039 31912
-
Chongqing, 중국
- 모병
- Mg0039 31908
-
Nanchang, 중국
- 모병
- Mg0039 31907
-
Suzhou, 중국
- 모병
- Mg0039 31902
-
-
-
-
-
Lublin, 폴란드
- 모병
- Mg0039 21206
-
-
-
-
-
Nice, 프랑스
- 모병
- Mg0039 20301
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Participant must be a minimum of 18 years of age inclusive at the time of signing the informed consent form (ICF)
-
Participant must have received at least 1 dose of investigational medicinal product (IMP) (rozanolixizumab or placebo) in MG0038
-
Participant for whom the investigator considers a favorable benefit/risk for participation
-
Participant who, alone or with assistance of the caregiver, is considered reliable and capable of adhering to the protocol visit schedule or medication intake according to the judgement of the investigator
-
Male or female
-
A female participant is eligible to participate if she is not, not breastfeeding (including pumping breastmilk to feed a child), and at least 1 of the following conditions applies:
- Not a woman of childbearing potential (WOCBP) OR
- A WOCBP who agrees to follow the contraceptive guidance for the entire study period
-
Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol
Exclusion Criteria:
- Participant meets any of the withdrawal criteria defined in MG0038
- Participant has a clinically relevant active infection (resulting in hospitalization or requiring intravenous (IV) antibiotic treatment) within 6 weeks before study entry.
- Participant intends to have a live vaccination during the study or within 8 weeks following the final dose of rozanolixizumab
- Participant has been administered with the prohibited immunosuppressive medications, biologics, or other therapies
- Participant has planned use of prohibited medications
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Rozanolixizumab
The study is composed of Extended Observation Period(s) and Symptom-driven Cycle(s). Based on their clinical need for treatment, study participants will be able to start the study with either an Extended Observation Period or a Symptom-driven Cycle. A Symptom-driven Cycle will be initiated based on disease worsening and participants will receive rozanolixizumab based on investigator's medical judgement. |
Rozanolixizumab will be administered by subcutaneous infusion.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of treatment-emergent adverse events (TEAEs)
기간: Up to 2 years
|
Treatment Emergent Adverse Events (TEAEs) are any untoward medical incidence in a participant after the administration of study treatment, whether or not these events are related to study treatment. |
Up to 2 years
|
|
Incidence of treatment-emergent serious adverse events (TESAEs)
기간: Up to 2 years
|
An SAE is defined as any untoward medical occurrence that, at any dose, meets 1 or more of the criteria listed:
|
Up to 2 years
|
|
Incidence of TEAEs leading to permanent withdrawal of study treatment
기간: Up to 2 years
|
Treatment Emergent Adverse Events (TEAEs) are any untoward medical incidence in a participant after the administration of study treatment, whether or not these events are related to study treatment. This measure considers any TEAE leading to permanent withdrawal from study. |
Up to 2 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from Baseline at Day 43 in (Myasthenia Gravis Impairment Index) MGII ocular score (Patient-Reported Outcome part)
기간: At Day 43 (of the first 3 Symptom-driven Cycles)
|
MGII is a measure of disease severity based on the signs and symptoms of MG patients. The MGII has 22 patient-reported items and 6 examination items and scores are presented as a sum of all items for a total score but also as an ocular and generalized sub-score. The scoring range is 0 to 84, 0-23 for the ocular score, and 0-61 for the generalized score, where higher scores are indicative of more severe symptoms. The recall period is "the past week". |
At Day 43 (of the first 3 Symptom-driven Cycles)
|
|
Change from Baseline at Day 43 in Myasthenia Gravis Activities of Daily Living (MG-ADL) ocular score
기간: At Day 43 (of the first 3 Symptom-driven Cycles)
|
The MG-ADL score is an 8-item patient-reported outcome (PRO) instrument. The MG-ADL targets symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability. The two ocular items will be summed for the ocular score, ranging from 0 to 6. |
At Day 43 (of the first 3 Symptom-driven Cycles)
|
|
Change from Baseline at Day 43 in Myasthenia Gravis Symptoms Patient-Reported Outcome (MGSPRO) ocular muscle weakness scale score
기간: At Day 43 (of the first 3 Symptom-driven Cycles)
|
The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (items 1-5); bulbar muscle weakness (items 6-15); respiratory muscle weakness (items 16-18); physical fatigue (items 19-33) and muscle weakness fatigability (items 34-42). Only the ocular muscle weakness scale will be used in this study. Ocular symptom severity is assessed over the past 7 days using a 4-point verbal rating scale (none, mild, moderate, severe) |
At Day 43 (of the first 3 Symptom-driven Cycles)
|
|
Change from Baseline at Day 43 in Myasthenia Gravis Quality of Life 15-item Scale (revised version) (MG-QoL15r) total score
기간: At Day 43 (of the first 3 Symptom-driven Cycles)
|
The MG-QoL15r is a 15-item PRO measure that is designed to assess aspects of health-related quality of life related to MG. The recall period that will be used is "past 7 days". Each item has 3 response options (0-2) and the total score ranges from 0 to 30, with higher scores indicating more severe impact on health-related QoL (HRQOL). |
At Day 43 (of the first 3 Symptom-driven Cycles)
|
|
Study participant who generalizes to Myasthenia Gravis Foundation of America (MGFA) class ≥2 over time
기간: Up to 2 years
|
MGFA Clinical Classification is a 5-stage classification (I to V), with a higher class indicating more severe disease. |
Up to 2 years
|
|
Change from Baseline in MGII total and generalized score over time
기간: Up to 2 years
|
MGII is a measure of disease severity based on the signs and symptoms of MG patients. The MGII has 22 patient-reported items and 6 examination items and scores are presented as a sum of all items for a total score but also as an ocular and generalized sub-score. The scoring range is 0 to 84, 0-23 for the ocular score, and 0-61 for the generalized score, where higher scores are indicative of more severe symptoms. The recall period is "the past week". |
Up to 2 years
|
|
Change from Baseline in MG-ADL total score over time
기간: Up to 2 years
|
The MG-ADL score is an 8-item patient-reported outcome (PRO) instrument. The MG-ADL targets symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability. The two ocular items will be summed for the ocular score, ranging from 0 to 6. |
Up to 2 years
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- MG0039
- 2025-524757-14-00 (씨티스)
- U1111-1334-3218 (기타 식별자: Universal Trial Number)
- CTR20262521 (레지스트리 식별자: ChinaDrugTrials.org.cn)
- 2025 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD 공유 기간
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD 공유 액세스 기준
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .